MoFo Life Sciences

December 22, 2023 - European Union, Asia, Healthcare
Standards for Inventiveness and Disclosure for Antibody Claims Across Jurisdictions
By: Karen G Potter Ph.D., Meghan McLean Poon Ph.D. and Paige Zhang Ph.D.
Standards for patenting antibodies have substantially tightened over the last few years restricting scope of antibody claims—or, in some cases, undermining the validity of granted patents. Most recently, Singapore updated guidelines to add a framework for analysis of antibody patentability. Although not all countries
... ›
March 28, 2023 - United States, Asia, European Union, Litigation, Intellectual Property
Recent Updates on Use of Post-filing Data as Evidence to Support Patentability
By: Liz Newman Ph.D. and Karen G Potter Ph.D.
In a “first to file” patent system as exists in the United States and in most countries throughout the world, timing of when to file a patent application is critically important but must be balanced by patentability requirements such as nonobviousness and enablement. This
... ›
March 23, 2023 - Biotech, Pharma, Licensing + Commercial, Asia, Regulatory
China Eyes New Export Controls for Life Sciences Technologies
By: Tyler Xiu, Bu Yin Ph.D., Gordon A. Milner, Chuan Sun and Janet Xiao Ph.D.
China is considering new export restrictions on advanced technologies, including, in particular, in the life sciences sectors. In late December 2022, China’s Ministry of Commerce (“ MOFCOM ”) issued the proposed amendment to the country’s Catalogue of Technologies Prohibited and Restricted for Export (the
... ›
July 18, 2022 - Agtech, Asia, Global, Intellectual Property, Litigation
IN VINEIS VERITAS: NO SOUR GRAPES AS EGYPTIAN COURT ORDERS REMOVAL OF ILLEGAL VINES
By: Liz Freeman Rosenzweig Ph.D.
The Beni Suef Economic Court in Egypt has recently ordered the removal of nearly five hectares of illegally grown Early Sweet™ grapevines, totaling 9000 vines and associated seedlings. The farm owner did not have a license to grow or commercialize the Early Sweet™ grapes
... ›
May 20, 2022 - Agtech, Intellectual Property, Asia
China’s New Seed Law: Molecular Varieties and Macro Developments
By: Liz Freeman Rosenzweig Ph.D.
Liz Freeman Rosenzweig co-authored an article for China IPR examining China's new and much anticipated Seed Law, which went into effect on March 1, 2022. "The new Seed Law reflects a significant expansion in the scope of plant breeders' rights (PRB) protection in China,"
... ›
September 30, 2020 - Agtech, Pharma, Regulatory, Asia
China Technology Export Update: Amendment of The Export Technology Catalog
On August 28, 2020, China’s Ministry of Commerce (MOFCOM) and Ministry of Science and Technology (MOST) jointly published a notice on the adjustment of China’s Catalog of Technologies the Export of Which is Prohibited or Restricted (the “Catalog”). This is the first time the
... ›
September 23, 2020 - Regulatory, Intellectual Property, Asia
China Patent Linkage Update: Codification and Rulemaking
On July 3, 2020, China’s National People’s Congress published the second draft of the latest amendment to China’s Patent Law (the “Draft Amendment”) for public comments, which were allowed to be submitted by August 16, 2020. The Draft Amendment included proposed revisions to 19
... ›
July 22, 2020 - Biotech, Pharma, Regulatory, Asia
China to Criminalize Human Genetic Resources Violations
On June 28, 2020, the draft 11 th amendment to China’s Criminal Law (the “Draft”) was submitted to the Standing Committee of the National People’s Congress for review. The Draft added a number of crimes intended to “connect” with certain provisions in China’s Human
... ›
July 10, 2020 - Biotech, Pharma, Regulatory, Asia
China’s Biosecurity Law will cover Human Genetic Resources
During its April 2020 meetings, the Standing Committee of China’s National People’s Congress reviewed a number of draft legislations, among which was a draft Biosecurity Law. At the conclusion of the meetings, the second draft of the Biosecurity Law (the “Draft”) was published for
... ›
May 22, 2020 - COVID-19, CFIUS, Healthcare, Asia
Japan Moves to Tighten Restrictions on Foreign Investment in Healthcare Industries
By: Gary Mitchel Smith
Amid concerns about predatory acquisitions of weakened companies and strategic assets during the COVID‑19 crisis, more and more countries are restricting foreign direct investment (FDI) in their domestic companies, especially in the medical and healthcare industries. These restrictions tend to target Chinese investment in
... ›

Topic Archives: Asia

Standards for Inventiveness and Disclosure for Antibody Claims Across Jurisdictions

By: Karen G Potter Ph.D., Meghan McLean Poon Ph.D. and Paige Zhang Ph.D.

Recent Updates on Use of Post-filing Data as Evidence to Support Patentability

By: Liz Newman Ph.D. and Karen G Potter Ph.D.

China Eyes New Export Controls for Life Sciences Technologies

By: Tyler Xiu, Bu Yin Ph.D., Gordon A. Milner, Chuan Sun and Janet Xiao Ph.D.

IN VINEIS VERITAS: NO SOUR GRAPES AS EGYPTIAN COURT ORDERS REMOVAL OF ILLEGAL VINES

By: Liz Freeman Rosenzweig Ph.D.

China’s New Seed Law: Molecular Varieties and Macro Developments

By: Liz Freeman Rosenzweig Ph.D.

China Technology Export Update: Amendment of The Export Technology Catalog

China Patent Linkage Update: Codification and Rulemaking

China to Criminalize Human Genetic Resources Violations

China’s Biosecurity Law will cover Human Genetic Resources

Japan Moves to Tighten Restrictions on Foreign Investment in Healthcare Industries

By: Gary Mitchel Smith